276 related articles for article (PubMed ID: 19732534)
21. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis.
Langley RG; Eichenfield LF; Lucky AW; Boguniewicz M; Barbier N; Cherill R
Pediatr Dermatol; 2008; 25(3):301-7. PubMed ID: 18577032
[TBL] [Abstract][Full Text] [Related]
22. 1% pimecrolimus cream for atopic dermatitis.
Eichenfield LF; Lucky AW; Boguniewicz M; Langley RG; Cherill R; Marshall K
Arch Dermatol; 2003 Oct; 139(10):1369-70; author reply 1370-1. PubMed ID: 14568846
[No Abstract] [Full Text] [Related]
23. Topical pimecrolimus and tacrolimus do not accelerate photocarcinogenesis in hairless mice after UVA or simulated solar radiation.
Lerche CM; Philipsen PA; Poulsen T; Wulf HC
Exp Dermatol; 2009 Mar; 18(3):246-51. PubMed ID: 19183401
[TBL] [Abstract][Full Text] [Related]
24. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial.
Leung DY; Hanifin JM; Pariser DM; Barber KA; Langley RG; Schlievert PM; Abrams B; Hultsch T
Br J Dermatol; 2009 Aug; 161(2):435-43. PubMed ID: 19416245
[TBL] [Abstract][Full Text] [Related]
25. Combination of low-dosage cyclosporine and topical pimecrolimus in severe atopic dermatitis with chronic hepatitis B.
Campione E; Paternò EJ; Diluvio L; Bianchi L; Giorgetti G; Chimenti S
Acta Derm Venereol; 2008; 88(1):74-5. PubMed ID: 18176762
[No Abstract] [Full Text] [Related]
26. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients.
Reitamo S; Rustin M; Harper J; Kalimo K; Rubins A; Cambazard F; Brenninkmeijer EE; Smith C; Berth-Jones J; Ruzicka T; Sharpe G; Taieb A;
Br J Dermatol; 2008 Sep; 159(4):942-51. PubMed ID: 18637898
[TBL] [Abstract][Full Text] [Related]
27. Eczema herpeticum during treatment of atopic dermatitis with 1% pimecrolimus cream.
Segura S; Romero D; Carrera C; Iranzo P; Estrach T
Acta Derm Venereol; 2005; 85(6):524-5. PubMed ID: 16396803
[No Abstract] [Full Text] [Related]
28. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance.
Langley RG; Luger TA; Cork MJ; Schneider D; Paul C
Dermatology; 2007; 215 Suppl 1():27-44. PubMed ID: 18174691
[TBL] [Abstract][Full Text] [Related]
29. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Munzenberger PJ; Montejo JM
Pharmacotherapy; 2007 Jul; 27(7):1020-8. PubMed ID: 17594208
[TBL] [Abstract][Full Text] [Related]
30. Pimecrolimus -- an anti-inflammatory drug targeting the skin.
Grassberger M; Steinhoff M; Schneider D; Luger TA
Exp Dermatol; 2004 Dec; 13(12):721-30. PubMed ID: 15560755
[TBL] [Abstract][Full Text] [Related]
31. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis.
Reitamo S; Mandelin J; Rubins A; Remitz A; Mäkelä M; Cirule K; Rubins S; Zigure S; Ho V; Dickinson J; Undre N
Int J Dermatol; 2009 Apr; 48(4):348-55. PubMed ID: 19335418
[TBL] [Abstract][Full Text] [Related]
32. [The use of analgesics in Denmark, 2000-2004].
Rosenzweig M; Nielsen AS
Ugeskr Laeger; 2006 May; 168(20):1975-81. PubMed ID: 16768899
[TBL] [Abstract][Full Text] [Related]
33. StabiEL: stabilization of skin condition with Elidel--a patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid.
Gollnick H; Luger T; Freytag S; Bräutigam M;
J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1319-25. PubMed ID: 18540990
[TBL] [Abstract][Full Text] [Related]
34. Molluscum contagiosum infection associated with pimecrolimus use in pityriasis alba.
Goksugur N; Ozbostanci B; Goksugur SB
Pediatr Dermatol; 2007; 24(5):E63-5. PubMed ID: 17958783
[TBL] [Abstract][Full Text] [Related]
35. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*.
Lakhanpaul M; Davies T; Allen BR; Schneider D
Exp Dermatol; 2006 Feb; 15(2):138-41. PubMed ID: 16433686
[TBL] [Abstract][Full Text] [Related]
36. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults.
Margolis DJ; Hoffstad O; Bilker W
Dermatology; 2007; 214(4):289-95. PubMed ID: 17460399
[TBL] [Abstract][Full Text] [Related]
37. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].
van der Laan JR
Ned Tijdschr Geneeskd; 2005 Aug; 149(32):1816; author reply 1817. PubMed ID: 16121669
[No Abstract] [Full Text] [Related]
38. [Topical calcineurin inhibitors in atopic eczema -- pro].
Wollenberg A
Dtsch Med Wochenschr; 2006 Jul; 131(28-29):1614. PubMed ID: 16823713
[No Abstract] [Full Text] [Related]
39. Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion.
Hartmann A; Bröcker EB; Hamm H
J Dtsch Dermatol Ges; 2008 May; 6(5):383-5. PubMed ID: 18042249
[TBL] [Abstract][Full Text] [Related]
40. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology.
Fonacier L; Spergel J; Charlesworth EN; Weldon D; Beltrani V; Bernhisel-Broadbent J; Boguniewicz M; Leung DY; ;
J Allergy Clin Immunol; 2005 Jun; 115(6):1249-53. PubMed ID: 15940142
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
